喹高利特治疗高泌乳素血症的疗效和安全性：系统评价和荟萃分析。

The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.

机构信息

Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Department of Neurosurgery, The Fifth Affiliated Hospital of Nanchang University (Fu Zhou First People's Hospital of Jiangxi Province), Fuzhou, Jiangxi, China.

出版信息

Front Endocrinol (Lausanne). 2023 Jan 24;14:1027905. doi: 10.3389/fendo.2023.1027905. eCollection 2023.

DOI:10.3389/fendo.2023.1027905

PMID:36761195

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9902948/

Abstract

PURPOSE

Three dopamine agonists [bromocriptine, cabergoline, and quinagolide (CV)] have been used for hyperprolactinemia treatment for decades. Several studies have reviewed the efficacy and safety of bromocriptine and cabergoline. However, no systematic review or meta-analysis has discussed the efficacy and safety of CV in hyperprolactinemia and prolactinoma treatment.

METHODS

Five medical databases (PubMed, Web of Science, Embase, Scopus, and Cochrane Library) were searched up to 9 May 2022 to identify studies related to CV and hyperprolactinemia. A meta-analysis was implemented by using a forest plot, funnel plot, sensitivity analysis, meta-regression, and Egger's test software R 4.0 and STATA 12.

RESULTS

A total of 1,211 studies were retrieved from the five medical databases, and 33 studies consisting of 827 patients were finally included in the analysis. The pooled proportions of patients with prolactin concentration normalization and tumor reduction (>50%) under CV treatment were 69% and 20%, respectively, with 95% confidence intervals of 61%-76% and 15%-28%, respectively. The pooled proportion of adverse effects was 13%, with a 95% confidence interval of 11%-16%.

CONCLUSION

Our study showed that CV is not less effective than cabergoline and bromocriptine in treating hyperprolactinemia, and the side effects were not significant. Hence, this drug could be considered an alternative first-line or rescue treatment in treating hyperprolactinemia in the future.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022347750.

摘要

目的

三种多巴胺激动剂[溴隐亭、卡麦角林和喹高利德（CV）]已被用于治疗高泌乳素血症数十年。已有多项研究对溴隐亭和卡麦角林的疗效和安全性进行了综述。然而，尚无系统评价或荟萃分析讨论 CV 在高泌乳素血症和催乳素瘤治疗中的疗效和安全性。

方法

检索了五个医学数据库（PubMed、Web of Science、Embase、Scopus 和 Cochrane Library），截至 2022 年 5 月 9 日，以确定与 CV 和高泌乳素血症相关的研究。使用森林图、漏斗图、敏感性分析、meta 回归和 Egger 检验软件 R 4.0 和 STATA 12 进行荟萃分析。